Dr. Sasine on Determining Outlook With CAR T-Cell Therapy in Hematologic Cancers

Video

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, University of California, Los Angeles, discusses how to determine if a patient will have a response to CAR T-cell therapy.

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, University of California, Los Angeles, discusses how to determine if a patient will have a response to CAR T-cell therapy.

Currently, it is difficult to determine who is going to benefit the most from CAR T-cell therapy, according to Sasine. However, researchers are getting closer to that because there are certain cytokine profiles now known, both before and after CAR T cells are given, that are associated with long-term, durable remissions, explains Sasine.

Lymphodepletion can also be a signal to determine response to CAR T cell therapy. This is something that can be modified within a physician's control, whereas other aspects are unmodifiable but can be helpful for predicting response.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
© 2025 MJH Life Sciences

All rights reserved.